Header Logo

Connection

Annette Langer-Gould to Retrospective Studies

Back to Details
This is a "connection" page, showing publications Annette Langer-Gould has written about Retrospective Studies.
Annette Langer-Gould
Connection Strength
1.713
Retrospective Studies
  1. Racial and Ethnic Disparities in the Incidence of Anti-NMDA Receptor Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2024 Jul; 11(4):e200255.
    View in: PubMed
    Score: 0.144
  2. Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections. Neurol Neuroimmunol Neuroinflamm. 2024 May; 11(3):e200211.
    View in: PubMed
    Score: 0.142
  3. Multiple Sclerosis, Disease-Modifying Therapies, and Infections. Neurol Neuroimmunol Neuroinflamm. 2023 Nov; 10(6).
    View in: PubMed
    Score: 0.138
  4. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis. JAMA Netw Open. 2022 12 01; 5(12):e2248664.
    View in: PubMed
    Score: 0.130
  5. Anakinra or high-dose corticosteroids in COVID-19 pneumonia patients who deteriorate on low-dose dexamethasone: an observational study of comparative effectiveness. Int J Infect Dis. 2023 Jan; 126:87-93.
    View in: PubMed
    Score: 0.130
  6. High-dose corticosteroids in patients hospitalized for COVID-19 pneumonia: an observational study of comparative effectiveness. Int J Infect Dis. 2022 Dec; 125:184-191.
    View in: PubMed
    Score: 0.129
  7. Racial and Ethnic Disparities in Multiple Sclerosis Prevalence. Neurology. 2022 05 03; 98(18):e1818-e1827.
    View in: PubMed
    Score: 0.125
  8. Multiple sclerosis, rituximab, and COVID-19. Ann Clin Transl Neurol. 2021 04; 8(4):938-943.
    View in: PubMed
    Score: 0.116
  9. Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies. Neurol Neuroimmunol Neuroinflamm. 2021 03; 8(2).
    View in: PubMed
    Score: 0.115
  10. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab. Int J Infect Dis. 2020 Oct; 99:291-297.
    View in: PubMed
    Score: 0.111
  11. Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflamm. 2020 07; 7(4).
    View in: PubMed
    Score: 0.109
  12. Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility. PLoS One. 2016; 11(3):e0149094.
    View in: PubMed
    Score: 0.081
  13. Immunomodulatory agents and risk of postpartum multiple sclerosis relapses. Perm J. 2014; 18(1):9-13.
    View in: PubMed
    Score: 0.070
  14. Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology. 2013 May 07; 80(19):1734-9.
    View in: PubMed
    Score: 0.067
  15. Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study. Mult Scler. 2023 05; 29(6):731-740.
    View in: PubMed
    Score: 0.033
  16. The intensity of anticoagulant dosing in hospitalized patients with COVID-19: An observational, comparative effectiveness study. J Hosp Med. 2023 01; 18(1):43-54.
    View in: PubMed
    Score: 0.032
  17. Validation of an algorithm for identifying MS cases in administrative health claims datasets. Neurology. 2019 03 05; 92(10):e1016-e1028.
    View in: PubMed
    Score: 0.025
  18. Association between maternal inflammatory bowel disease and adverse perinatal outcomes. J Perinatol. 2014 Jun; 34(6):435-40.
    View in: PubMed
    Score: 0.018

© 2024 Kaiser Permanente